The rational manipulation of antigen-specific T cells to reignite a tumor-specific immune
response in cancer patients is a challenge for cancer immunotherapy. Targeting coinhibitory …

Background Vaccination against tumor-associated antigens is one promising approach to
immunotherapy against malignant gliomas. While previous vaccine efforts have focused …

T regulatory cells are able to suppress anti-tumour immunity in pre-clinical models and in
patients. This review highlights the important discoveries in Treg immunology critical to the …

DNA vaccines can induce impressive specific cellular immune response (IR) when taking
advantage of their recognition as pathogen-associated molecular patterns (PAMP) through …

In this study, biodegradable cationic polycarbonate and polylactide block copolymers were
synthesized and successfully used as novel vaccine adjuvants to provide enhanced …

We have evaluated the capacity of a novel, nanoparticle-based tumor vaccine to eradicate
established tumors in mice. C57BL/6 mice were intradermally (id) inoculated with ovalbumin …

Anticancer active immunotherapy embodies the ideal antitumor therapy, as it theoretically
combines target specificity with long-term disease control. Peptide-based cancer vaccines …

Major advances in the knowledge of cancer biology and its interactions with tumor immune
environment led to the emergence, in the last five years of new immunotherapy-based …

T cell–based therapies have much promise in cancer treatment. This approach may be
enhanced if used in combination with radiotherapy provided that tumor-specific T cells can …

Objective (s): Program death 1 (PD-1)/program death-ligand 1 (PD-L1) pathways, as the
main inhibitory checkpoints, induce immunosuppression in the tumor microenvironment …